Drug reference
surufatinib
Small-molecule tyrosine kinase inhibitor · Antineoplastic agent
Small-molecule tyrosine kinase inhibitorAntineoplastic agentATC L01EX16
CDSCO approvedATC L01EX16
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Surufatinib is a VEGFR-targeted tyrosine kinase inhibitor. It inhibits the signaling pathways associated with Vascular Endothelial Growth Factor (VEGF), particularly through VEGFR2, which plays a crucial role in promoting angiogenesis, cell growth, proliferation, and survival in neuroendocrine tumors.
Indications
Advanced pancreatic neuroendocrine tumors (NETs)Extrapancreatic neuroendocrine tumors (NETs)
Dosing
- Adult
- 300 mg daily (in randomized trial).
Related guidelines
Ask House about surufatinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team